# Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure

> **NCT00026169** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 69 (estimated)

## Conditions studied

- Malignant Neoplasm
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** imatinib mesylate
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00026169
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-09
- **Primary completion:** 2005-04
- **Final completion:** —
- **Target enrollment:** 69 (ESTIMATED)
- **Last updated:** 2013-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00026169

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00026169, "Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00026169. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*